Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.

Several signaling cascades are engaged by expression of the p210 bcr-abl tyrosine kinase, and evidence suggests that these signals drive leukemogenesis. In this report, signaling pathways were examined and compared between cells derived from leukemic patients and cells expressing a bcr-abl construct (MBA). The effects of acute inhibition of bcr-abl with STI-571 on these signals and the survival of bcr-abl-expressing cells were also evaluated. Expression of bcr-abl in interleukin-3 (IL-3)/granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent Mo7e cells (MBA) resulted in growth factor independence, constitutive activation of Stat-5 phosphorylation, engagement of mitogen-activated protein (MAP) kinase signals, and increased expression of PTP1B and bcl-x(L). STI-571 inhibited cell growth and induced apoptosis in bcr-abl-expressing cells (MBA, K562, BV-173, KBM5) but not in bcr-abl(-) tumor cells (Mo7e, KG-1, ME-180, Daudi). STI-571-mediated apoptosis correlated with the inhibition of Stat-5 and MAP kinase activation and a reduction in overexpressed bcl-x(L) but not in PTP1B. Inhibitor had no effect on IL-3/GM-CSF-dependent Mo7e cell signaling and did not prevent activation of the other Jak/Stat pathways (interferon alpha, IL-3/GM-CSF). However, neither IL-3 nor GM-CSF could reactivate Stat-5 after the STI-571-mediated inhibition of bcr-abl. Expression of the common beta-chain of the IL-3/GM-CSF receptor was down-regulated in Stat-5-activated myeloid leukemic cells, suppressing IL-3/GM-CSF signal transduction and the ability of these cytokines to provide apoptotic protection. These studies suggest that bcr-abl activates cytokine-independent mechanisms of survival while inactivating intrinsic cytokine signaling cascades, making bcr-abl(+) myeloid cells vulnerable to apoptosis after bcr-abl inactivation.

[1]  J. Gutkind,et al.  Loss of PTEN expression leading to high Akt activation in human multiple myelomas. , 2000, Blood.

[2]  S. Arkinstall,et al.  Identification of Tyrosine Phosphatases That Dephosphorylate the Insulin Receptor , 2000, The Journal of Biological Chemistry.

[3]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[4]  J. Griffin,et al.  STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. , 2000, Blood.

[5]  G. Stark,et al.  Association of STATs with relatives and friends. , 2000, Trends in cell biology.

[6]  F. Gouilleux,et al.  Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line , 2000, Oncogene.

[7]  John Calvin Reed,et al.  The Survival Function of the Bcr-Abl Oncogene Is Mediated by Bad-Dependent and -Independent Pathways: Roles for Phosphatidylinositol 3-Kinase and Raf , 2000, Molecular and Cellular Biology.

[8]  O. Witte,et al.  Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. White,et al.  Tyrosine Dephosphorylation and Deactivation of Insulin Receptor Substrate-1 by Protein-tyrosine Phosphatase 1B , 2000, The Journal of Biological Chemistry.

[10]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[11]  C. Schindler,et al.  Cytokines and STAT signaling. , 2000, Advances in pharmacology.

[12]  S. Gisselbrecht.  The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. , 1999, European cytokine network.

[13]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[14]  J. Griffin,et al.  BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis , 1999, Molecular and Cellular Biology.

[15]  C. Eaves,et al.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Hunter,et al.  The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.

[17]  T. Naka,et al.  Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. , 1999, Trends in biochemical sciences.

[18]  A. Yoshimura,et al.  Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway. , 1999, Experimental hematology.

[19]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[20]  R. Jove,et al.  STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. , 1999, Blood.

[21]  F. Gouilleux,et al.  IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line , 1999, Oncogene.

[22]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[23]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[24]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[25]  B. Calabretta,et al.  Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis , 1999, The Journal of Experimental Medicine.

[26]  J. Lammers,et al.  STAT 5 Activation by BCR-Abl Contributes to Transformation of K 562 Leukemia Cells , 1999 .

[27]  Z. Estrov,et al.  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Abraham,et al.  Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. , 1998, Current opinion in immunology.

[29]  R. Jove,et al.  Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. , 1998, Journal of biomedical science.

[30]  B. Franza,et al.  Protein Tyrosine Phosphatase 1B Antagonizes Signalling by Oncoprotein Tyrosine Kinase p210 bcr-abl In Vivo , 1998, Molecular and Cellular Biology.

[31]  D. Green,et al.  Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL , 1998, Oncogene.

[32]  N. Donato,et al.  Tumor Necrosis Factor-induced Apoptosis Stimulates p53 Accumulation and p21WAF1 Proteolysis in ME-180 Cells* , 1998, The Journal of Biological Chemistry.

[33]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[34]  C. Sawyers,et al.  Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.

[35]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[36]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[37]  J. Licht,et al.  Transcription factors, normal myeloid development, and leukemia. , 1997, Blood.

[38]  C. Preudhomme,et al.  Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) , 1997, Leukemia.

[39]  K. Mitani.  Leukemogenesis by the chromosomal translocations. , 1997, Leukemia.

[40]  B. Calabretta,et al.  Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. , 1997, Critical reviews in eukaryotic gene expression.

[41]  R. V. van Etten,et al.  P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.

[42]  L. Varticovski,et al.  BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. , 1996, Leukemia.

[43]  J. Wilson-Rawls,et al.  P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. , 1996, Cancer research.

[44]  J. Griffin,et al.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.

[45]  J. Dick,et al.  Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. , 1994, Blood.

[46]  M. Hung,et al.  Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[47]  B. Franza,et al.  Multi‐site phosphorylation of the protein tyrosine phosphatase, PTP1B: identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation. , 1993, The EMBO journal.

[48]  O. Witte,et al.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence , 1993, Molecular and cellular biology.

[49]  T. Pandita,et al.  Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. , 1992, Cancer research.

[50]  N. Copeland,et al.  Chromosomal localization and organization of the murine genes encoding the beta subunits (AIC2A and AIC2B) of the interleukin 3, granulocyte/macrophage colony-stimulating factor, and interleukin 5 receptors. , 1992, The Journal of biological chemistry.

[51]  A. Miyajima,et al.  Two distinct functional high affinity receptors for mouse interleukin‐3 (IL‐3). , 1992, The EMBO journal.

[52]  O. Witte,et al.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner , 1991, Cell.

[53]  Christopher T Denny,et al.  Leukemia and the disruption of normal hematopoiesis , 1991, Cell.

[54]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[55]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[56]  H. Mikawa,et al.  Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. , 1989, Leukemia.

[57]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.